Benzinga | Jun 16, 2021 07:23AM EDT

Citigroup Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $68

Citigroup analyst Neena Bitritto-Garg downgrades Sage Therapeutics (NASDAQ:SAGE) from Buy to Neutral and lowers the price target from $101 to $68.